Bank of America Boosts Humana (HUM) Price Target to $415.00

Humana (NYSE:HUM) had its target price upped by research analysts at Bank of America from $400.00 to $415.00 in a report issued on Thursday. The brokerage currently has a “buy” rating on the insurance provider’s stock. Bank of America’s target price indicates a potential upside of 22.44% from the stock’s current price.

Several other brokerages have also recently weighed in on HUM. Jefferies Financial Group increased their price target on shares of Humana from $388.00 to $410.00 and gave the company a “buy” rating in a research report on Thursday. MED raised their target price on shares of Humana from $350.00 to $373.00 and gave the stock an “outperform” rating in a research report on Thursday. Cowen started coverage on shares of Humana in a research report on Monday, September 17th. They issued a “market perform” rating and a $372.00 target price for the company. SunTrust Banks raised their target price on shares of Humana to $380.00 and gave the stock a “hold” rating in a research report on Wednesday, September 19th. Finally, Credit Suisse Group raised their target price on shares of Humana from $350.00 to $370.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 4th. Seven investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Humana presently has a consensus rating of “Buy” and a consensus price target of $352.30.

HUM traded down $0.64 during trading on Thursday, hitting $338.95. 780,088 shares of the stock traded hands, compared to its average volume of 655,197. The stock has a market capitalization of $48.77 billion, a P/E ratio of 25.36, a PEG ratio of 1.73 and a beta of 1.03. The company has a quick ratio of 1.43, a current ratio of 1.43 and a debt-to-equity ratio of 0.47. Humana has a 12-month low of $231.90 and a 12-month high of $355.88.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, November 7th. The insurance provider reported $4.58 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $4.29 by $0.29. The business had revenue of $14.21 billion during the quarter, compared to analysts’ expectations of $13.97 billion. Humana had a net margin of 2.70% and a return on equity of 19.36%. During the same quarter in the prior year, the company posted $3.39 EPS. Sell-side analysts expect that Humana will post 14.44 EPS for the current fiscal year.

In related news, CEO Bruce D. Broussard sold 18,000 shares of Humana stock in a transaction dated Monday, September 10th. The shares were sold at an average price of $328.66, for a total transaction of $5,915,880.00. Following the completion of the transaction, the chief executive officer now directly owns 71,085 shares of the company’s stock, valued at approximately $23,362,796.10. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Elizabeth D. Bierbower sold 3,092 shares of Humana stock in a transaction dated Thursday, August 16th. The shares were sold at an average price of $330.00, for a total transaction of $1,020,360.00. Following the transaction, the insider now directly owns 14,289 shares of the company’s stock, valued at $4,715,370. The disclosure for this sale can be found here. Company insiders own 0.60% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of HUM. Stratos Wealth Partners LTD. purchased a new position in Humana during the 3rd quarter valued at about $108,000. Sun Life Financial INC increased its stake in Humana by 120.7% during the 2nd quarter. Sun Life Financial INC now owns 373 shares of the insurance provider’s stock valued at $111,000 after purchasing an additional 204 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its stake in Humana by 2,984.6% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 401 shares of the insurance provider’s stock valued at $119,000 after purchasing an additional 388 shares in the last quarter. Smithfield Trust Co. increased its stake in Humana by 531.2% during the 3rd quarter. Smithfield Trust Co. now owns 486 shares of the insurance provider’s stock valued at $165,000 after purchasing an additional 409 shares in the last quarter. Finally, Girard Partners LTD. bought a new stake in Humana during the 3rd quarter valued at about $169,000. 92.62% of the stock is owned by institutional investors.

Humana Company Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.

Recommended Story: Risk Tolerance and Your Investment Decisions

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply